Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Life Sciences Industry Analysis

UpdatedJun 07, 2026
DataAggregated Company Financials
Companies64
  • 7D-1.5%
  • 3M1.4%
  • 1Y11.5%
  • YTD-13.9%

Over the last 7 days, the Life Sciences industry has dropped 1.5%, driven by Thermo Fisher Scientific declining 4.0%. Over the past 12 months, the industry was up 11%. As for the next few years, earnings are expected to grow by 17% per annum.

Industry Valuation and Performance

Has the U.S. Life Sciences Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sun, 07 Jun 2026US$586.3bUS$150.6bUS$13.8b37.8x42.6x3.9x
Tue, 05 May 2026US$545.1bUS$149.1bUS$13.7b36.3x39.7x3.7x
Thu, 02 Apr 2026US$555.7bUS$147.8bUS$14.1b36.9x39.4x3.8x
Sat, 28 Feb 2026US$597.8bUS$147.9bUS$14.0b35.2x42.8x4x
Mon, 26 Jan 2026US$693.6bUS$145.8bUS$12.4b36x56.1x4.8x
Wed, 24 Dec 2025US$660.8bUS$145.8bUS$12.5b35.2x53x4.5x
Fri, 21 Nov 2025US$645.6bUS$145.7bUS$12.2b34.2x53x4.4x
Sun, 19 Oct 2025US$627.0bUS$144.3bUS$14.6b33x43.1x4.3x
Tue, 16 Sep 2025US$565.3bUS$144.3bUS$14.6b29.2x38.8x3.9x
Thu, 14 Aug 2025US$568.9bUS$144.2bUS$14.4b30.4x39.5x3.9x
Sat, 12 Jul 2025US$541.8bUS$142.9bUS$9.1b37.2x59.3x3.8x
Mon, 09 Jun 2025US$518.0bUS$142.9bUS$9.2b35.6x56.5x3.6x
Wed, 07 May 2025US$521.1bUS$142.6bUS$9.6b36.1x54.1x3.7x
Fri, 04 Apr 2025US$568.9bUS$142.6bUS$10.0b36.3x57x4x
Sun, 02 Mar 2025US$605.3bUS$143.3bUS$9.7b38.1x62.3x4.2x
Tue, 28 Jan 2025US$701.1bUS$142.4bUS$10.2b46x68.7x4.9x
Thu, 26 Dec 2024US$658.4bUS$142.4bUS$10.2b44.7x64.4x4.6x
Sat, 23 Nov 2024US$653.1bUS$142.4bUS$10.4b44.1x63.1x4.6x
Mon, 21 Oct 2024US$736.4bUS$141.8bUS$8.5b37.2x86.7x5.2x
Wed, 18 Sep 2024US$744.9bUS$141.8bUS$8.5b37.5x87.7x5.3x
Fri, 16 Aug 2024US$729.5bUS$141.5bUS$8.4b38.9x87.2x5.2x
Sun, 14 Jul 2024US$685.9bUS$141.2bUS$12.2b40.7x56.2x4.9x
Tue, 11 Jun 2024US$712.9bUS$141.3bUS$12.2b37.7x58.5x5x
Thu, 09 May 2024US$715.1bUS$141.5bUS$12.8b38.4x56x5.1x
Sat, 06 Apr 2024US$719.2bUS$142.1bUS$12.8b43.1x56.2x5.1x
Mon, 04 Mar 2024US$744.0bUS$142.2bUS$12.8b44.2x58.1x5.2x
Wed, 31 Jan 2024US$707.1bUS$148.2bUS$12.5b39.5x56.6x4.8x
Fri, 29 Dec 2023US$704.8bUS$153.8bUS$14.2b38.1x49.5x4.6x
Sun, 26 Nov 2023US$642.9bUS$153.8bUS$14.0b34.7x45.9x4.2x
Tue, 24 Oct 2023US$604.8bUS$154.6bUS$11.2b31.1x54x3.9x
Thu, 21 Sep 2023US$684.3bUS$154.6bUS$11.2b32.1x61.1x4.4x
Sat, 19 Aug 2023US$707.9bUS$154.6bUS$11.2b32.5x63.2x4.6x
Mon, 17 Jul 2023US$706.1bUS$155.5bUS$12.7b29.3x55.7x4.5x
Wed, 14 Jun 2023US$698.2bUS$152.4bUS$12.5b29.2x55.8x4.6x
Price to Earnings Ratio

55.8x


Total Market Cap: US$698.2bTotal Earnings: US$12.5bTotal Revenue: US$152.4bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Life Sciences Industry Price to Earnings3Y Average 56.4x202420252026
Current Industry PE
  • Investors are pessimistic on the American Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 42.6x which is lower than its 3-year average PE of 56.4x.
  • The 3-year average PS ratio of 4.4x is higher than the industry's current PS ratio of 3.9x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences industry have grown 3.2% per year over the last three years, while revenues have remained mostly flat.
  • This means that companies overall are more efficiently conducting business since profits are increasing while sales have been flat.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market-2.79%
Healthcare0.81%
Life Sciences-1.54%
Clinical Research and Equipment-1.54%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
DHR DanaherUS$184.300.9%
+US$1.2b		-6.0%PE35.5x
ICLR ICONUS$149.459.8%
+US$1.0b		7.4%PE49.9x
TXG 10x GenomicsUS$31.049.7%
+US$347.2m		229.5%PS6.2x
ADPT Adaptive BiotechnologiesUS$16.9011.6%
+US$280.1m		67.5%PS9.2x
IQV IQVIA HoldingsUS$183.450.7%
+US$207.0m		20.4%PE22.1x

Latest News

BRKR
US$56.39
Bruker
7D
-4.2%
1Y
47.2%
RVTY
US$98.37
Revvity
7D
-5.9%
1Y
7.0%
MEDP
US$454.25
Medpace Holdings
7D
1.6%
1Y
53.2%
ADPT
US$16.90
Adaptive Biotechnologies
7D
11.6%
1Y
67.5%
TMO
US$472.80
Thermo Fisher Scientific
7D
-4.0%
1Y
17.6%
ICLR
US$149.45
ICON
7D
9.8%
1Y
7.4%
IQV
US$183.45
IQVIA Holdings
7D
0.7%
1Y
20.4%
TEM
US$46.43
Tempus AI
7D
-8.0%
1Y
-25.2%
BIO
US$294.32
Bio-Rad Laboratories
7D
-5.8%
1Y
34.1%
Narrative Update • Jun 04

BIO: Activist Pressure And Buybacks Will Shape Future Value Realization

Analysts have reaffirmed their $320.00 price target for Bio-Rad Laboratories, citing adjusted assumptions for discount rate, revenue growth, profit margin, and future P/E as the main factors behind the updated view. What's in the News Activist investor Elliott Investment Management has taken a significant stake in Bio-Rad Laboratories after the stock declined more than 70% from its late 2021 peak, and is publicly pushing for improvements in the share price and company performance.
TXG
US$31.04
10x Genomics
7D
9.7%
1Y
229.5%
WAT
US$365.36
Waters
7D
-4.7%
1Y
4.0%
Narrative Update • Jun 03

WAT: New Omics Platforms And Buybacks Will Support Future Upside

Analysts have trimmed their price target for Waters to $460, reflecting slightly higher assumed discount rates, modestly adjusted long term revenue growth and profit margin expectations, and a lower future P/E multiple in their updated models. What's in the News Waters launched the Cyclic IMS P20 Mass Spectrometer, a structural and spatial omics platform using multipass Cyclic Ion Mobility Spectrometry and advanced fragmentation and imaging techniques, aimed at earlier detection of disease signals and more detailed molecular visualization.
MTD
US$1,154.33
Mettler-Toledo International
7D
-2.2%
1Y
-2.5%
Narrative Update • Jun 03

MTD: Automation And Emerging Markets Will Support EPS Upside Despite Geopolitical Risks

Analysts have trimmed their average price target for Mettler-Toledo International from about $1,344.50 to roughly $1,327.83. This reflects updated assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E expectations.
DHR
US$184.30
Danaher
7D
0.9%
1Y
-6.0%
WST
US$314.50
West Pharmaceutical Services
7D
-2.6%
1Y
40.0%
FTRE
US$16.08
Fortrea Holdings
7D
4.5%
1Y
204.5%
Narrative Update • May 25

FTRE: Conservative 2026 Guidance And AI Tools May Drive Re Rating

Analysts raised Fortrea Holdings’ fair value estimate to $20.00 from $16.00, citing updated assumptions on discount rates, revenue growth, profit margins, and future P/E that are consistent with a series of recent price target increases across the Street. Analyst Commentary Recent Street research around Fortrea has shifted toward a more constructive tone, with several bullish analysts lifting price targets and one firm moving the stock to a higher rating category.
BLFS
US$26.65
BioLife Solutions
7D
6.9%
1Y
12.4%